HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Harshit Jain, MD
Programmatic Marketing

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement